Hans-Heinrich Henneicke-Von Zepelin

Hans-Heinrich Henneicke-Von Zepelin

Auto-generated profile, based on publicly available information

Hans-Heinrich Henneicke-Von Zepelin

Tiakis Biotech AG, Kiel, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

14 July 2021 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
PSPetra Stute
Petra Stute
SEStefan Ehrentraut
Stefan Ehrentraut
HZHans-Heinrich Henneicke-Von Zepelin
Hans-Heinrich Henneicke-Von Zepelin
PNPetra Nicken
Petra Nicken
Purpose: This study aimed at assessing gene expression profiles in hippocampus and hypothalamus of ovariectomized (OVX) rats with or without treatment with an isopropanolic extract of Cimicifuga racemosa rhizomes (iCR) in comparison to intact rats. Methods: Exploration of hippocampal (Hi) and hypothalamic (Hy) tissue from Sprague Dawley rats: without OVX (NHi = NHy = 4), tissues 3 months after OVX (NHi = 4, NHy = 3), or tissues of rats after their treatment with iCR for 3 months after OVX (NHi = NHy = 2). Gene expression profiles in these tissues were investigated by RNA-microarray-analysis and subsequent verification by qPCR. Results: 4812 genes were differentially regulated when comparing the three groups in hippocampus and hypothalamus. iCR compensated the effects of OVX in 518 genes. This compensatory effect was most prominent in hippocampal signalling pathways, thereof genes (GAL, CALCA, HCRT, AVPR1A, PNOC, etc.) involved in thermoregulation, regulation of sleep and arousal, blood pressure regulation, metabolism, nociception, hormonal regulation, homeostasis, learning and cognition, mood regulation, neuroendocrine modulation, etc.. In the hypothalamus, iCR compensated OVX-effects at TAC3 and OPRM1 but not at KISS1. These genes are involved in the pathophysiology of hot flashes. Conclusions: Our pilot study findings support a multifaceted mode of action of iCR in menopausal complaints on a tissue-specific brain gene expression level.

9 September 2019 in Zeitschrift für Phytotherapie
Verified
Conference Paper
Closed access
PNP Nicken
P Nicken
HZHh Henneicke-Von Zepelin
Hh Henneicke-Von Zepelin
JKJc Kuchernig
Jc Kuchernig
SPS Pickartz
S Pickartz
NNN Naser
N Naser
KNKu Nolte
Ku Nolte
Menopausal transition makes 50 to 85% of women experience symptoms affecting their well-being and quality of life. Licensed Cimicifuga racemosa (CR) medicinal products are efficacious against vasomotor symptoms (VMS), with isopropanolic extract (iCR) exhibiting best evidence [1, 2]. The mode of action is not fully known as the pathophysiology of VMS is still unclear. Circulating peripheral estrogen levels are not correlated with VMS [3]. The pace of estrogen depletion causes imbalances of serotonin- and noradrenalin levels (and others) in the thermoregulatory center, resulting in VMS [4 – 7]. The hypothalamic thermoregulatory center appears to be the most likely site of thermoregulatory dysfunction [8]. Hypothalamic KNDy neurons seem to participate in the generation of hot flushes [9]. Transformations in the postmenopausal brain include upregulation of KISS1 and TAC3 mRNA (encoding the KNDy-peptides kisspeptin and neurokinin) in distinct hypothalamic nuclei [10]. Also, calcitonin gene-related peptide seems to be involved in menopausal VMS [11]. References (e.g. MEDLINE, EMBASE, BIOSIS) was collected till 2019 and analyzed for CR interacting with brain receptors or modulating brain activity and brain metabolism. iCR alleviates ovariectomy (OVX)-induced impaired thermoregulation [12]. iCR binds to serotonin, dopamine, GABA and µ-opioid brain receptors leading to receptor-mediated functional activity [13 – 16]. CR/iCR modulates the ratio of cerebral monoamines and metabolites [17] as well as serotonergic and dopaminergic brain activity (EEG) [18] and µ-opioid receptor availability [19]. In addition, iCR ameliorates OVX-induced changes of the serotonergic and noradrenergic brainstem-preoptic anterior hypothalamus pathways [20, 21]. OVX reduced the adaptability of hypothalamic neurons to respond to temperature changes and iCR compensated these changes by increasing neuronal activity [4, 22]. Moreover iCR/CR exerts anti-inflammatory, antioxidant and radical scavenger activity [23 – 28]. In distinct brain regions, iCR compensates OVX-induced upregulation of genes relevant for thermoregulation, mood, cognition and other menopause-associated dysfunctions [29]. These CR properties may be important as estrogen decline and fluctuations cause oxidative stress and neuroinflammation, resulting in „dysregulation” in the hypothalamic thermoregulatory area and possibly other central brain regions (e.g. hippocampus). We hypothesize that CR/iCR is able to initiate functional recovery of the hypothalamic thermo-regulatory area and thus, to mitigate VMS by a multifaceted set of mechanisms. These may include a direct action on serotonin, dopamine and µ-opioid receptors in connection with modulation of VMS-relevant gene expression and anti-inflammatory, antioxidant and radical scavenger activities. The data show a non-estrogenic multi-target mode of action of CR alleviating menopausal symptoms including VMS. iCR binds to CNS receptors, modulates neuropeptide-based pathways, brain function and metabolism involved in thermoregulation and other climacteric symptoms. Further research is ongoing to elucidate the neuromodulating action of CR. References: [1] Beer AM, Neff A. Evid Based Complement Alternat Med 2013; 2013: 860602 [2] Beer AM et al. Gynecol Endocrinol 2013; 29: 1022 – 1025 [3] Sturdee DW et al. Climacteric 2017; 20: 296 – 305 [4] Hui Z et al. J Ethnopharmacol 2012; 142: 769 – 775 [5] Garcia de Arriba S et al. Z Phytother 2013; 34(Suppl.1): S29 [6] Danilovich N. Exp Neurol 2003; 183: 559 – 572 [7] Benedusi V et al. Endocrinology 2012; 153: 2777 – 2788 [8] Freedman RR. Am J Med 2005; 118: 124 – 130 [9] Rance NE et al. Front Neuroendocrinol 2013; 34: 211 – 227 [10] Skorupskaite K et al. Neuroendocrinology 2018; 106: 148 – 157 [11] Oliveira MA et al. Endocrine 2019; 63: 193 – 203 [12] Ma X et al. J Ethnopharmacol 2011; 138: 156 – 161 [13] Burdette JE et al. J Agric Food Chem 2003; 51: 5661 – 5670 [14] Powell SL et al. J Agric Food Chem 2008; 56: 11718 – 11726 [15] Nisslein T et al. Maturitas 2006; 54: S65 [16] Rhyu MR et al. J Agric Food Chem 2006; 54: 9852 – 9857 [17] Nadaoka I et al. Natural Product Communications 2012; 7: 15 – 18 [18] Garcia de Arriba S et al. Maturitas 2015; 82: 318 [19] Reame NE et al. Menopause 2008; 15: 832 – 840 [20] Wang W et al. Neuroendocrinology 2015; 101: 120 – 132 [21] Wang W et al. Ann Anat 2016; 208: 31 – 39 [22] Ma X et al. J Int Obstet Gynecol 2011; 38: 148 – 154 [23] Burdette JE et al. J Agric Food Chem 2002; 50: 7022 – 7028 [24] Nuntanakorn P et al. J Nat Prod 2006; 69: 314 – 318 [25] Kim SJ, Kim MS. Phytother Res 2000; 14: 596 – 600 [26] Schmid D et al. J Pharm Pharmacol 2009; 61: 1089 – 1096 [27] Schmid D et al. Can J Physiol Pharmacol 2009; 87: 963 – 972 [28] Da Y et al. PLoS One 2015; 10: e0121470 [29] Stute P. Latest insights into iCR's mode of action. Congress of European Menopause and Andropause Society. Berlin

23 November 2006 in Zeitschrift für Phytotherapie
Verified
Journal Article
Closed access
HZHh Henneicke-Von Zepelin
Hh Henneicke-Von Zepelin
HMH Meden
H Meden
DSD Schröder-Bernhardi
D Schröder-Bernhardi
KKK Kostev
K Kostev
HBH Becher
H Becher
Der isopropanolische Cimicifuga-racemosa-Extrakt (iCR, enthalten in Remifemin® und Remifemin® plus) wirkt gegen Wechseljahresbeschwerden. Seine Sicherheit bei Brustkrebsüberlebenden, einschließlich Östrogen-abhängiger Tumoren, hinsichtlich des rezidivfreien Überlebens untersuchten wir mittels dieser pharmakoepidemiologischen retrospektiven Kohortenstudie. Die Daten stammen aus allgemeinen, gynäkologischen sowie internistischen Praxen in Deutschland, die der IMS-Datenbank Mediplus angeschlossen sind. Der Hauptzielparameter war das rezidivfreie Überleben. Der Einfluss einer iCR-Therapie bei Brustkrebsüberlebenden wurde mittels Cox-Regressionen analysiert, in die das Alter, die Tamoxifen-Anwendung sowie weitere Einflussgrößen einbezogen wurden und die relative Hazard-Raten lieferten. Von 18861 Patientinnen hatten 1102 iCR durchschnittlich 1,5 Jahre erhalten. Die mittlere Beobachtungsdauer betrug 3,6 Jahre. iCR war mit einem signifikant längeren rezidivfreien Überleben assoziiert. Zwei Jahre nach der Initialdiagnose hatten 14% der Kontrollgruppe ein Rezidiv entwickelt, während die iCR-Gruppe diese Rezidivrate erst nach 6,5 Jahren erreichte. Das primäre Cox-Regressionsmodell ergab für das rezidivfreie Überleben eine relative Hazard-Rate von 0,83 zu Gunsten der iCR-Gruppe (95%-Konfidenzintervall 0,69–0,99). Dieses Ergebnis erwies sich als konsistent in allen Variationen des statistischen Modells, einschließlich Subgruppenanalysen. Der TNM-Status der Patientinnen war zwar unbekannt, doch da er die iCR-Therapie-Entscheidung nicht beeinflusst, ist seine gleichmäßige Verteilung auf die Gruppen annehmbar. Die Datenbank wies eine gute interne und externe Validität auf. Das rezidivfreie Überleben von Brustkrebspatientinnen wird durch iCR-haltige Arzneimittel nicht negativ beeinflusst.

19 January 2026 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
IBIngmar Bergs
Ingmar Bergs
SBStephan Budweiser
Stephan Budweiser
HZHans-Heinrich Henneicke-Von Zepelin
Hans-Heinrich Henneicke-Von Zepelin
HKHagen Kelm
Hagen Kelm
TBTom Bollmann
Tom Bollmann
MDMichael Dreher
Michael Dreher

10 August 2021 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
PSPetra Stute
Petra Stute
SEStefan Ehrentraut
Stefan Ehrentraut
HZHans-Heinrich Henneicke-Von Zepelin
Hans-Heinrich Henneicke-Von Zepelin
PNPetra Nicken
Petra Nicken